Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program. The alliance ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback